HUP0401898A3 - 3-substituted-4-pyrimidone derivatives, pharmaceutical compositions containing them and their intermediates - Google Patents
3-substituted-4-pyrimidone derivatives, pharmaceutical compositions containing them and their intermediatesInfo
- Publication number
- HUP0401898A3 HUP0401898A3 HU0401898A HUP0401898A HUP0401898A3 HU P0401898 A3 HUP0401898 A3 HU P0401898A3 HU 0401898 A HU0401898 A HU 0401898A HU P0401898 A HUP0401898 A HU P0401898A HU P0401898 A3 HUP0401898 A3 HU P0401898A3
- Authority
- HU
- Hungary
- Prior art keywords
- intermediates
- substituted
- pharmaceutical compositions
- compositions containing
- pyrimidone derivatives
- Prior art date
Links
- -1 3-substituted-4-pyrimidone Chemical class 0.000 title 1
- 239000000543 intermediate Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001331675 | 2001-09-21 | ||
JP2001331678 | 2001-09-21 | ||
JP2001331674 | 2001-09-21 | ||
JP2001331676 | 2001-09-21 | ||
PCT/JP2002/009684 WO2003027080A1 (en) | 2001-09-21 | 2002-09-20 | 3-substituted-4-pyrimidone derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0401898A2 HUP0401898A2 (hu) | 2004-12-28 |
HUP0401898A3 true HUP0401898A3 (en) | 2005-08-29 |
Family
ID=27482650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0401898A HUP0401898A3 (en) | 2001-09-21 | 2002-09-20 | 3-substituted-4-pyrimidone derivatives, pharmaceutical compositions containing them and their intermediates |
Country Status (24)
Country | Link |
---|---|
US (1) | US7572793B2 (hu) |
EP (1) | EP1427709B1 (hu) |
JP (1) | JP4368682B2 (hu) |
KR (1) | KR100754596B1 (hu) |
CN (1) | CN1319950C (hu) |
AR (2) | AR043700A1 (hu) |
AT (1) | ATE312827T1 (hu) |
AU (1) | AU2002337498B2 (hu) |
BR (1) | BR0212893A (hu) |
CA (1) | CA2460177C (hu) |
CY (1) | CY1105554T1 (hu) |
DE (1) | DE60208051T2 (hu) |
DK (1) | DK1427709T3 (hu) |
EA (1) | EA007224B1 (hu) |
ES (1) | ES2256540T3 (hu) |
HK (1) | HK1068608A1 (hu) |
HU (1) | HUP0401898A3 (hu) |
IL (2) | IL160701A0 (hu) |
MX (1) | MXPA04002661A (hu) |
NO (1) | NO326694B1 (hu) |
NZ (1) | NZ531637A (hu) |
PL (1) | PL368816A1 (hu) |
TW (1) | TWI303171B (hu) |
WO (1) | WO2003027080A1 (hu) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR023052A1 (es) | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
CA2460121C (en) | 2001-09-21 | 2010-11-02 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
JP4616003B2 (ja) * | 2002-12-16 | 2011-01-19 | 田辺三菱製薬株式会社 | 3−置換−4−ピリミドン誘導体 |
EP1608317B1 (en) | 2003-03-25 | 2012-09-26 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
TWI357408B (en) * | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
US7579357B2 (en) | 2003-08-13 | 2009-08-25 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
JP2007505121A (ja) | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
CN102127057A (zh) | 2004-03-15 | 2011-07-20 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
TW200621760A (en) * | 2004-09-09 | 2006-07-01 | Mitsubishi Pharma Corp | 2-morpholino-4-pyrimidone compound |
EP1805164B9 (en) | 2004-09-29 | 2011-09-07 | Mitsubishi Tanabe Pharma Corporation | 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors |
JP2008524331A (ja) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
GB0510141D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
TW200740779A (en) * | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
ZA200802857B (en) | 2005-09-14 | 2009-09-30 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
KR101368988B1 (ko) | 2005-09-16 | 2014-02-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 디펩티딜 펩티다제 억제제 |
TW200813015A (en) * | 2006-03-15 | 2008-03-16 | Mitsubishi Pharma Corp | 2-(cyclic amino)-pyrimidone derivatives |
ATE530540T1 (de) * | 2006-08-23 | 2011-11-15 | Pfizer Prod Inc | Pyrimidonverbindungen als gsk-3-inhibitoren |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
AR064660A1 (es) | 2006-12-26 | 2009-04-15 | Mitsubishi Tanabe Pharma Corp | Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
US8288383B2 (en) * | 2007-09-14 | 2012-10-16 | Sanofi | 3-methyl-2- ( (2S) -2- (4- (3-methyl-L, 2, 4-oxadiazol-5-YL) phenyl) morpholino) -6- (pyrim-idin-4-yl) pyrimidin-4 (3H) -one as tau protein kinase inhibitor |
EP2078717A1 (en) | 2008-01-11 | 2009-07-15 | sanofi-aventis | 6-Pyrimidinyl-pyrimid-2-one derivative |
EA201070367A1 (ru) * | 2007-09-14 | 2010-08-30 | Мицубиси Танабе Фарма Корпорейшн | Производное 6-пиримидинилпиримид-4-она |
AR076014A1 (es) | 2009-04-02 | 2011-05-11 | Sanofi Aventis | Derivados de 3- (1,4) oxazepan -4-pirimidona |
WO2011019090A1 (en) | 2009-08-13 | 2011-02-17 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone derivatives used as tau protein kinase 1 inhibitors |
WO2011019089A1 (en) | 2009-08-13 | 2011-02-17 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone derivatives used as tau protein kinase 1 inhibitors |
WO2011119842A1 (en) | 2010-03-25 | 2011-09-29 | The J. David Gladstone Institutes | Compositions and methods for treating neurological disorders |
CN106729771A (zh) | 2011-04-21 | 2017-05-31 | 加利福尼亚大学董事会 | 官能化磁性纳米颗粒及在淀粉样沉积物和神经原纤维缠结成像中用途 |
ES2554843T3 (es) * | 2012-01-12 | 2015-12-23 | F. Hoffmann-La Roche Ag | Derivados heterocíclicos como receptores asociados de trazas de amina (TAARs) |
US9567395B2 (en) | 2012-08-16 | 2017-02-14 | Ipierian, Inc. | Methods of treating a tauopathy |
CN110818798A (zh) | 2012-10-25 | 2020-02-21 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
EP2914291B1 (en) | 2012-11-02 | 2022-02-23 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
MX370723B (es) | 2013-06-10 | 2019-12-20 | Ipierian Inc | Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatía. |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US187004A (en) * | 1877-02-06 | Improvement in water-wheels | ||
JPS559099B2 (hu) | 1972-08-07 | 1980-03-07 | ||
JPS4935633A (hu) | 1972-08-09 | 1974-04-02 | ||
JPS5124008B2 (hu) | 1972-08-10 | 1976-07-21 | ||
JPS4935632A (hu) | 1972-08-10 | 1974-04-02 | ||
JPS5271481A (en) | 1975-12-10 | 1977-06-14 | Yoshitomi Pharmaceut Ind Ltd | Synthesis of pyridylpyrimidines |
JPS52139085A (en) | 1976-05-13 | 1977-11-19 | Hokuriku Pharmaceutical | 22allylpiperazine derivative and method for its preparation |
US4507302A (en) * | 1979-03-19 | 1985-03-26 | The Upjohn Company | Method for treating arthritis with 6-aryl pyrimidine compounds |
US4619933A (en) * | 1979-09-28 | 1986-10-28 | The Upjohn Company | 6-aryl pyrimidines for treating aplastic anemia |
US4725600A (en) | 1984-07-13 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent |
ATE107633T1 (de) * | 1988-04-22 | 1994-07-15 | Zeneca Ltd | Pyrimidinon-derivate. |
DE58908208D1 (de) | 1988-07-29 | 1994-09-22 | Ciba Geigy Ag | Thiouracile als Stabilisatoren für chlorhaltige Polymerisate. |
US6200768B1 (en) | 1991-12-06 | 2001-03-13 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Method of screening for compounds that dissolve paired helical filaments |
DE4206145A1 (de) * | 1992-02-28 | 1993-09-02 | Basf Ag | Herbizide n-((pyrimidin-2-yl)aminocarbonyl)benzolfulfonamide |
JP3324611B2 (ja) | 1992-07-03 | 2002-09-17 | 三菱化学株式会社 | タウ蛋白質のリン酸化方法 |
JPH06329551A (ja) | 1993-03-22 | 1994-11-29 | Mitsubishi Kasei Corp | アルツハイマー病の予防または治療薬およびそのスクリーニング方法 |
CZ101496A3 (en) * | 1993-10-12 | 1996-11-13 | Du Pont Merck Pharma | N-alkyl-n-aryl-pyrimidinamines and derivatives thereof |
US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
US6410729B1 (en) | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
JP2002514195A (ja) | 1996-12-05 | 2002-05-14 | アムジエン・インコーポレーテツド | 置換ピリミジン化合物およびそれの使用 |
HUP0001698A3 (en) | 1996-12-05 | 2002-07-29 | Amgen Inc Thousand Oaks | Substituted pyrimidine compounds and their use |
CZ9902016A3 (cs) | 1996-12-05 | 1999-11-17 | Amgen Inc. | Substituované pyrimidinonové a pyridonové sloučeniny a způsoby jejich použití |
CA2285445C (en) * | 1997-03-26 | 2007-06-12 | Taisho Pharmaceutical Co., Ltd. | 4-tetrahydropyridylpyrimidine derivative |
AR023052A1 (es) * | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
ATE293962T1 (de) * | 2000-02-25 | 2005-05-15 | Hoffmann La Roche | Adenosin-rezeptor modulatoren |
EP1136482A1 (en) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
WO2001070728A1 (en) | 2000-03-23 | 2001-09-27 | Sanofi-Synthelabo | 2-[nitrogen-heterocyclic]pyrimidone derivatives |
CA2460121C (en) | 2001-09-21 | 2010-11-02 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
JP4616003B2 (ja) | 2002-12-16 | 2011-01-19 | 田辺三菱製薬株式会社 | 3−置換−4−ピリミドン誘導体 |
TWI357408B (en) | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
-
2002
- 2002-09-20 KR KR1020047004113A patent/KR100754596B1/ko not_active IP Right Cessation
- 2002-09-20 DK DK02772870T patent/DK1427709T3/da active
- 2002-09-20 CN CNB028180178A patent/CN1319950C/zh not_active Expired - Fee Related
- 2002-09-20 BR BR0212893-4A patent/BR0212893A/pt not_active Application Discontinuation
- 2002-09-20 AR ARP020103546A patent/AR043700A1/es unknown
- 2002-09-20 WO PCT/JP2002/009684 patent/WO2003027080A1/en active IP Right Grant
- 2002-09-20 NZ NZ531637A patent/NZ531637A/en not_active IP Right Cessation
- 2002-09-20 HU HU0401898A patent/HUP0401898A3/hu unknown
- 2002-09-20 JP JP2003530670A patent/JP4368682B2/ja not_active Expired - Lifetime
- 2002-09-20 MX MXPA04002661A patent/MXPA04002661A/es active IP Right Grant
- 2002-09-20 AR ARP020103547A patent/AR036604A1/es active IP Right Grant
- 2002-09-20 CA CA2460177A patent/CA2460177C/en not_active Expired - Fee Related
- 2002-09-20 AU AU2002337498A patent/AU2002337498B2/en not_active Ceased
- 2002-09-20 AT AT02772870T patent/ATE312827T1/de active
- 2002-09-20 PL PL02368816A patent/PL368816A1/xx not_active Application Discontinuation
- 2002-09-20 IL IL16070102A patent/IL160701A0/xx unknown
- 2002-09-20 EA EA200400452A patent/EA007224B1/ru not_active IP Right Cessation
- 2002-09-20 EP EP02772870A patent/EP1427709B1/en not_active Expired - Lifetime
- 2002-09-20 TW TW091121652A patent/TWI303171B/zh active
- 2002-09-20 US US10/489,607 patent/US7572793B2/en not_active Expired - Fee Related
- 2002-09-20 DE DE60208051T patent/DE60208051T2/de not_active Expired - Lifetime
- 2002-09-20 ES ES02772870T patent/ES2256540T3/es not_active Expired - Lifetime
-
2004
- 2004-03-03 IL IL160701A patent/IL160701A/en not_active IP Right Cessation
- 2004-04-20 NO NO20041604A patent/NO326694B1/no not_active IP Right Cessation
- 2004-12-07 HK HK04109693A patent/HK1068608A1/xx not_active IP Right Cessation
-
2006
- 2006-03-09 CY CY20061100327T patent/CY1105554T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0401898A3 (en) | 3-substituted-4-pyrimidone derivatives, pharmaceutical compositions containing them and their intermediates | |
HUP0401900A3 (en) | 3-substituted-4-pyrimidone derivatives, pharmaceutical compositions containing them and their intermediates | |
HUP0400467A3 (en) | 2-iminopyrrolidine derivatives, pharmaceutical compositions containing them and their use | |
HUP0600592A2 (en) | Substituted imidazopyridines, pharmaceutical compositions containing them and intermediates | |
IL162200A (en) | 17a - ALKYL - 17?? - OXY - ESTRATRIENES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND INTERMEDIATES FOR THEIR PRODUCTION | |
HUP0401718A3 (en) | Bicyclic oxopyridine and oxopyrimidine derivatives, their use and pharmaceutical compositions containing them | |
ZA200403682B (en) | N-adamantylmethyl derivatives and intermediates as pharmaceutical composition and processes for their preparation. | |
EP1450824A4 (en) | PHARMACEUTICAL COMPOSITION | |
HUP0201278A3 (en) | Pyrazolecarboamide derivative, its preparation, pharmaceutical compositions containing it and its intermediates | |
HUP0402566A3 (en) | C-5 modified indazolylamino pyrrolotriazines, their use and pharmaceutical compositions containing them | |
HUP0301508A3 (en) | Antiviral azaindole derivatives, pharmaceutical compositions containing them and intermediates | |
HUP0400837A3 (en) | 2-phenyl-thiazole derivatives, their use and pharmaceutical compositions containing them | |
HUP0204474A3 (en) | 1h-imidazopyridine derivatives, pharmaceutical compositions containing them and their use | |
IL158898A0 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING APOMORPHINE, 6aR-(-)-N-PROPYL-NORAPOMORPHINE AND DERIVATIVES THEREOF | |
HUP0500024A3 (en) | 6-aminomorphinane derivatives, their use and pharmaceutical compositions containing them | |
HUP0303163A3 (en) | Tramadol-based pharmaceutical composition | |
GB0117057D0 (en) | Pharmaceutical composition | |
HUP0401403A3 (en) | 2,4-diaminothiazole derivatives, their use and pharmaceutical compositions containing them | |
EP1408896A4 (en) | PHARMACEUTICAL COMPOSITION | |
GB0129117D0 (en) | Pharmaceutical composition | |
HUP0401654A3 (en) | Heterokondensated pyrimidine derivatives, their intermediates, preparations of the compounds and pharmaceutical compositions containing them | |
HUP0402028A3 (en) | Unsaturated 1-amino-alkylcyclohexane derivatives, pharmaceutical compositions containing them and use thereof | |
AU2001292331A1 (en) | 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation | |
AU2001292331A2 (en) | 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation | |
HK1068277A1 (en) | Pharmaceutical compositions comprising chelidonineor derivatives thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB9A | Succession in title |
Owner name: SANOFI-AVENTIS, FR Free format text: FORMER OWNER(S): MITSUBISHI PHARMA CORPORATION, JP; SANOFI-SYNTHELABO, FR Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JP Free format text: FORMER OWNER(S): MITSUBISHI PHARMA CORPORATION, JP; SANOFI-SYNTHELABO, FR |
|
FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |